AFRICSanté, la Recherche, l'Expertise et la Formation en Santé au profit de toute la communauté...

Vision et Ambition

Notre vision Contribuer à l’amélioration de la santé de la reproduction, notamment celle de la mère et de l’enfant au Burkina Faso et dans la sous–région ouest Africaine. Nos missions Servir de guide opérationnel pour l’action aux structures, instituts, organisations intervenant dans le domaine de la santé de la reproduction ; Servir de cadre (...)

Lire la suite...

Costing universal access of highly active antiretroviral therapy in Benin.

 

Hounton SH, Akonde A, Zannou DM, Bashi J, Meda N, Newlands D. Costing universal access of highly active antiretroviral therapy in Benin. AIDS Care 2008May ; 20(5):582-7.

Abstract

The study aimed to estimate costs of provision and access to highly active antiretroviral therapy (HAART) in order to assist in planning and resource allocation regarding scaling up and sustainable access to HAART in Benin. A prospective study was carried out to collect data on costs of provision of care at the Outpatient Treatment Centre (OTC) of the National University hospital in Cotonou, Benin and on costs borne by people living with HIV/AIDS (PLWHA) and their families in accessing care. We used an Excel model, a macro costing approach and WHO guidelines for costing health services. Annual costs were subsequently extrapolated from a societal perspective over a 10-year time horizon. Sensitivity analysis was conducted on major cost categories. The study population was mostly of middle age (median age of 38, IQR 34-42), married (65%), working class (60%) with low literacy (70% primary education level or less). The main drivers of costs of HAART service provision were drugs (73%), biological monitoring (15%) and personnel (8%). Annual costs of provision of HAART and household costs borne by PLWHA and families in seeking care amounted to 1160 USD and 111 USD per PLWHA respectively. These household costs are respectively 40% and 14% of household health and education related costs and may represent catastrophic health expenditures for patients and families. The provision of drugs and biological monitoring, and household costs in accessing care, remain by far the main barriers to ensuring universal access to HAART.

Lire la suite

 

  Publication AFRICSanté

RESEARCH ARTICLE Prevalence of and Factors Associated with Human Cysticercosis in 60 Villages in Three Provinces of Burkina Faso


Hélène Carabin1*, Athanase Millogo2, Assana Cissé3, Sarah Gabriël4, Ida Sahlu5,6, Pierre Dorny4, Cici Bauer7, Zekiba Tarnagda8, Linda D Cowan1†, (...)

Lire la suite...

 

RESEARCH ARTICLE :The obstetric care subsidy policy in Burkina Faso : what are the effects after five years of implementation ? Findings of a complex evaluation


Rasmané Ganaba1*, Patrick G. C. Ilboudo1, Jenny A. Cresswell2, Maurice Yaogo1, Cheick Omar Diallo3, Fabienne Richard4, Nadia Cunden5, Veronique (...)

Lire la suite...

 

 

 

ADRESSES :

Siège : Bobo-Dioulasso au 773, rue Guillaume Ouedraogo

BURKINA FASO

01 BP : 01 BP 298 Bobo-Dioulasso 01

Email : africsante@gmail.com

Tél : +226 20 98 63 68 —Fax : +226 20 98 63 69

 

 

 

Copyright©AFRICSanté 2014